NCT01932125CompletedPhase 4
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice
Source: ClinicalTrials.gov · Last updated 26 Jun 2025
Brief summary (registry, in English)
This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 27 Aug 2013
- Start date
- 5 Dec 2018
- Primary completion date
- 18 Jun 2025
- Lead sponsor
- Hoffmann-La Roche
- Diseases
- Ovarian cancer
- NCT number
- NCT01932125
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 100
- From 5 Dec 2018 to the primary completion date, 18 Jun 2025
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not eligible for treatment with bevacizumab according to the local prescribing information
Who the study is looking for
- Prescribed to receive bevacizumab or already ongoing on treatment with bevacizumab for advanced/metastatic ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) according to routine clinical practice
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Manipal Hospital Coordinator of this site? Confirm its status | Bangalore | India | Unknown status |
| HealthCare Global Enterprises Limited Coordinator of this site? Confirm its status | Banglore | India | Unknown status |
| Marthwada Regional Cancer Center & Research Institute Coordinator of this site? Confirm its status | Chhatrapati Sambhajinagar | India | Unknown status |
| MAX Balaji Hospital Coordinator of this site? Confirm its status | Delhi | India | Unknown status |
| Peerless Hospitex Hospital and Research Center Ltd. Coordinator of this site? Confirm its status | Kolkata | India | Unknown status |
| MOC Cancer Care & Research Centre Coordinator of this site? Confirm its status | Mumbai | India | Unknown status |
| HCG NCHRI Cancer Center Coordinator of this site? Confirm its status | Nagpur | India | Unknown status |
| Apex Wellness Hospital Coordinator of this site? Confirm its status | Nashik | India | Unknown status |
| HCG Manavata Cancer Centre Coordinator of this site? Confirm its status | Nashik | India | Unknown status |
| Rajiv Gandhi Cancer Inst.&Research Center Coordinator of this site? Confirm its status | New Delhi | India | Unknown status |
| Sahyadri Speciality Hospital Coordinator of this site? Confirm its status | Pune | India | Unknown status |
| Jehangir Clinical Development Centre Pvt. Ltd Coordinator of this site? Confirm its status | Pune | India | Unknown status |
| Grant Medical Foundation Ruby Hall Clinic Coordinator of this site? Confirm its status | Pune | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.